# Blue Earth Therapeutics

Source: https://onco.cc/companies/blue-earth-therapeutics/  
OnCo record `blue-earth-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Blue Earth Therapeutics makes radioactive drugs that seek out a protein on prostate cancer cells (PSMA), for men whose cancer has spread and no longer responds to hormone treatment. Its lutetium-177 medicine is in a phase 2 trial, and an actinium-225 version entered its first human trial in 2026.

## Summary

Blue Earth Therapeutics Ltd (Oxford Science Park, UK) was established by Bracco Imaging in 2021 to develop radioligand therapies based on radiohybrid PSMA (rhPSMA) chemistry. Its first outside financing, a USD 76.5 million Series A, was announced on 30 October 2024, led by Soleus Capital and co-led by Sands Capital Management, with Bracco Imaging, Woodline Partners and PBM Capital. The lead candidate, lutetium (177Lu) rhPSMA-10.1, reported key phase 1 results in March 2025 and began a phase 2 trial in metastatic castration-resistant prostate cancer in May 2025, with the first UK patients dosed in January 2026; it received a UK MHRA Innovation Passport in 2022. The alpha-emitting actinium (225Ac) rhPSMA-10.1, manufactured with Seibersdorf Labor, dosed its first phase 1 participant in July 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Oxford
- Type: radiopharma
- Website: https://www.blueearththerapeutics.com/

## Notes

- Included because the October 2024 Series A was its first announced outside financing; the company was set up by Bracco Imaging in 2021 (per the Series A release) and was already in the clinic before the round. The website does not state a founding year, so `founded` is omitted. Trial dates are from the company's news page.

## Sources

- Official website: https://www.blueearththerapeutics.com/
- Series A press release: https://www.prnewswire.com/news-releases/blue-earth-therapeutics-ltd-announces-completion-of-76-5m-series-a-financing-to-accelerate-development-of-next-generation-targeted-radioligand-therapies-302290606.html
- Pipeline: https://www.blueearththerapeutics.com/pipeline
- News: https://www.blueearththerapeutics.com/news

## Connected records

- companies: [Blue Earth Diagnostics (Bracco)](https://onco.cc/companies/blue-earth-diagnostics/)
- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Lutetium-177 radioligand therapy](https://onco.cc/technologies/lu177-radioligand-therapy/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- targets: [PSMA](https://onco.cc/targets/psma/)

---
JSON: https://onco.cc/api/v1/entities/blue-earth-therapeutics.json